necrostatin-7: a necroptosis inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 1239801 |
| CHEMBL ID | 514242 |
| SCHEMBL ID | 12682782 |
| MeSH ID | M0525664 |
| Synonym |
|---|
| HMS621M06 , |
| necrotatin-7 |
| CHEMBL514242 |
| necrostatin-7 |
| AKOS001738191 |
| 351062-08-3 |
| mfcd02140208 |
| STK763743 , |
| (5z)-5-{[3-(4-fluorophenyl)-1h-pyrazol-4-yl]methylidene}-2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one |
| (5z)-5-[[5-(4-fluorophenyl)-1h-pyrazol-4-yl]methylidene]-2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one |
| nec-7 |
| 5-[[3-(4-fluorophenyl)-1h-pyrazol-4-yl]methylene]-2-imino-3-(2-thiazolyl)-4-thiazolidinone |
| SMJGLNVGTJLIRV-KBEFMPHXSA-N |
| 5'-[3-(4-fluoro-phenyl)-1h-pyrazol-4-ylmethylene]-2'-imino-[2,3']bithiazolyl-4'-one |
| (5z)-5-([3-(4-fluorophenyl)-1h-pyrazol-4-yl]methylene)-2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one # |
| SCHEMBL12682782 |
| sr-01000531116 |
| SR-01000531116-1 |
| DTXSID40361283 |
| J-019941 |
| 5-((3-(4-fluorophenyl)-1h-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one |
| nec 7 |
| necrostatin7 |
| necrostatin 7 |
| nec7 |
| CS-0064314 |
| HY-117200 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID387464 | Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat cells | 2008 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18 | Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||